Effects of High Oleic Palm Olein (HOPO), Virgin Olive Oil (OO) and Refined Bleached and Deodorized (RBD) Coconut Oil (CO) Diets on Lipid Profile, Markers of Insulin Resistance, Inflammatory and Obesity in Overweight Subject.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 2
- 主要终点
- change in c-peptide level
研究概览
简要总结
This study will be comparing human body responses by the effects of diets cooked with NoveLin, virgin olive oil and RBD coconut oil.
详细描述
NoveLin has high content of monounsaturate fatty acids - oleic acid (C18:1) which is the predominant fatty acid and in this study NoveLin is used as cooking fat in compare with olive oil. Olive oil is the world's most commonly eaten monounsaturated oil which contains 55 - 83% oleic acid. Consumption of olive oil gives numerous health benefits on lowering total and LDL cholesterol, reducing LDL cholesterol's, lowering blood clotting factors, and lowering blood pressure. Coconut oil is the richest source of medium chain fatty acid and it has greater than 90% of saturated fatty acid with dominant fatty acid of lauric acid (C12:0). RBD coconut oil is used as positive control in this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 20 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •males and females aged 20-60 years
- •BMI 23 - 27.5 kg/m2
- •free from any disease
- •not on any medication or treatment associated with reduction of CVD
- •non-smokers and non-heavy drinker or having smoking or alcoholic history
- •not pregnant or lactating
- •willing and able to comply
排除标准
- •people on weight reduction therapy/program
- •people on cholesterol reduction medicatio
- •have one or more of the chronic diseases
- •people with blood clotting problem/ coagulopathy / deep vein thrombosis.
- •hypertensive persons (systolic pressure > 140 mmHg, diastolic pressure > 90 mmHg)
- •female who is pregnant
- •people travel to overseas during feeding.
结局指标
主要结局
change in c-peptide level
时间窗: week 0(baseline) and week 6
次要结局
- change in insulin resistance's markers(week 0(baseline) and week 6)
- change in obesity markers(week 0(baseline) and week 6)
- change in physical characteristic (eg. BMI, body weight)(week 0(baseline) and week 6)
- change in inflammatory markers(week 0(baseline) and week 6)
- change in lipid profile(week 0(baseline) and week 6)